Open | $0.768 |
Close | $0.876 |
Volume / Avg. | 40.931K / 154.124K |
Day Range | 0.768 - 0.877 |
52 Wk Range | 0.250 - 1.600 |
Market Cap | $28.020M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 69 |
Short Interest | 0.72% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Orgenesis (NASDAQ: ORGS) through any online brokerage.
Other companies in Orgenesis’s space includes: Fortress Biotech (NASDAQ:FBIO), Acurx Pharmaceuticals (NASDAQ:ACXP), OncoCyte (NASDAQ:OCX), Sensei Biotherapeutics (NASDAQ:SNSE) and Eledon Pharma (NASDAQ:ELDN).
The latest price target for Orgenesis (NASDAQ: ORGS) was reported by Benchmark on Wednesday, June 14, 2023. The analyst firm set a price target for 6.00 expecting ORGS to rise to within 12 months (a possible 631.26% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Orgenesis (NASDAQ: ORGS) is $0.8205 last updated March 15, 2024 at 7:28 PM EDT.
There are no upcoming dividends for Orgenesis.
Orgenesis’s Q1 earnings are confirmed for Wednesday, May 8, 2024.
There is no upcoming split for Orgenesis.
Orgenesis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.